Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3

Status Recruiting

Clinical Trial Summary

This study evaluates the effectiveness of oral trehalose in alleviating the neuropathological and motor behaviour deficits among patients with SCA3. A total of 40 participants with SCA3 will be recruited, with 20 participants to be administered with trehalose while another 20 participants to be administered with a maltose placebo.

Clinical Trial Description

Spinocerebellar ataxia 3 (SCA3) is a rare form of inherited neurodegenerative disease involving progressive degeneration of spinocerebellar tract. SCA3 is characterised by increasingly worsening cerebellar function leading to gait abnormalities and poor coordination, dysarthria, and abnormal eye movements. Non-ataxia features include pyramidal and extrapyramidal manifestations, sensorimotor, neuropsychological and psychiatric symptoms. This is attributed to the role of cerebellum in motor, cognitive and affective processing (i.e. cerebellar cognitive and affective syndrome; CCAS), as well as its extensive connection with cerebral structures. Trehalose is an omnipotent disaccharide molecule found in lower and higher life forms except in vertebrates. It has an amorphous (i.e. non-reducing) property, which is shown in its high hydrophilicity, chemical stability and strong resistance to denaturation / breakdown by heat, acid or enzyme. It is also shown to help refold partially denatured protein, thereby stabilizes protein aggregates, including those of polyglutamine, in vivo as well as in vitro. This has provided an avenue in which trehalose as a therapeutic agent for neurodegenerative disorders with pathological changes of protein aggregates. In this study, a double-blinded randomised controlled trial (RCT) will be employed. A total of 40 patients with SCA3 will be randomly allocated to oral trehalose group and a placebo group (20 participants for each arm). With regards to clinical outcomes, motor and cognitive performances will be assessed to infer the efficacy of trehalose. Likewise, structural, resting-state fMRI (i.e. functional connectivity), and MR spectroscopy (i.e. metabolism), will be used as imaging biomarkers in this study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04399265
Study type	Interventional
Source	National University of Malaysia
Contact	Kah Hui Yap, Master
Phone	+60165536721
Email	kahhui0411@gmail.com
Status	Recruiting
Phase	N/A
Start date	February 24, 2020
Completion date	June 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00992771` - Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3	Phase 2
Completed	`NCT01096082` - Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3	Phase 2/Phase 3
Active, not recruiting	`NCT03701399` - Troriluzole in Adult Subjects With Spinocerebellar Ataxia	Phase 3
Active, not recruiting	`NCT04229823` - Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD
Active, not recruiting	`NCT04419974` - Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes
Terminated	`NCT05490563` - STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia	Phase 2/Phase 3
Withdrawn	`NCT04301284` - Study of CAD-1883 for Spinocerebellar Ataxia	Phase 2
Withdrawn	`NCT01096095` - Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3	Phase 2
Active, not recruiting	`NCT04268147` - Instrumented Data Exchange for Ataxia Study
Recruiting	`NCT01793168` - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Active, not recruiting	`NCT05826171` - Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia	N/A
Completed	`NCT03885167` - Identification of Biomarkers in Spinocerebellar Ataxia 3
Terminated	`NCT05160558` - A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3	Phase 1
Recruiting	`NCT05822908` - A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD	Phase 1/Phase 2
Not yet recruiting	`NCT03378414` - Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia	Phase 2
Completed	`NCT05502432` - Repetitive Transcranial Magnetic Stimulation in SCA3 Patients	N/A
Recruiting	`NCT04714307` - Neuropsychiatry and Cognition in SCA3/MJD
Recruiting	`NCT05557786` - Treatment of Transcranial Alternating Current Stimulation（tACS）on Cerebellar Ataxia
Recruiting	`NCT01060371` - Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.